Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Roprostim N01 plus high-dose dexamethasone and IVIg for newly diagnosed severe ITP
ChiCTR2600134746Phase 4Not yet recruiting
- Sponsor
- First Affiliated Hospital of Nanchang University
- Start
- Nov 2026
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of QL0911 in immune thrombocytopenia (ITP) (2 arms), sponsored by First Affiliated Hospital of Nanchang University. Primary endpoint: Proportion of patients achieving persistent platelet response at week 12. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
QL0911
03
Conditions
immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on ChiCTR2600134746.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600134746.